First-in-human study on pharmacokinetics, safety, and tolerability of single and multiple escalating doses of hepenofovir, a novel hepatic targeting prodrug of tenofovir in healthy chinese subjects

HIGHLIGHTS

• who: Hong Zhang and collaborators from the Takasaki University of Health and Welfare, Japan have published the paper: First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects, in the Journal: (JOURNAL)
• what: All subjects recruited for this study provided written informed consent prior to their enrollment.
• how: The results showed that hepenofovir treatment can significantly reduce HBV DNA levels in the serum and liver with a dosedependent inhibitory effect that is described in detail . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.